Aptamer and Nanocarrier Coupling Cytotoxicity Study Service
CD Bioparticles offers a service for cytotoxicity studies of aptamers coupled to nanocarriers. We have extensive experience in the field of cytotoxicity assays and can offer to determine the toxicity to cells and organisms based on your different nanomaterials. Choosing to work with us will provide you with quality results and shorten your study cycle.
ApDC Coupling Cytotoxicity Study Service Background
NPs may enter the human body through oral administration, implantation, intravenous injection, and percutaneous absorption, raising public concerns about the adverse effects of NPs. Once in the human circulatory system, NPs spontaneously adsorb proteins, thereby reducing their surface-free energy. In addition, NPs can interact with cell membranes, lipids, proteins, and DNA to trigger various biological effects such as cell membrane disruption, oxidative stress, apoptosis, inflammation, and autophagy, which may ultimately lead to cytotoxicity. Therefore, the study of NP-induced cytotoxicity is essential for human health.
The toxicity and cytotoxicity of nanomaterials are complex and depend on various factors such as chemical composition, crystal structure, size (at the nanoscale, the basic physicochemical properties of the material vary with size), or aggregation. The composition of a nanomaterial determines its chemical interaction with cells, cellular uptake mechanisms, and intracellular localization. The chemical composition may also induce oxidative stress.
Fig. 1 Aptamers conjugated to AuNPs and immobilised on a glass plate (chip). The aptamer binds to the target bacteria modifying the absorption peaks of the AuNPs. In solutions without the pathogen the absorption peaks remain identical to the baseline AuNP absorption peak. AuNP: gold nanoparticles. (Gutiérrez-Santana JC, et al., 2020)
Our ApDC Coupling Cytotoxicity Study Services
CD Bioparticles offers toxicity assays for targeted drug delivery to cells based on the coupling of different nanocarrier materials with aptamers. Cytotoxicity studies are an important and crucial step in testing new substances/nanomaterials in the context of biological and medical applications. Our service process focuses on the following, including but not limited to these.
-
Aptamer-nanocarrier toxicity assays on cells
-
Aptamer-nanocarrier uptake assays on cells
-
Aptamer-nanocarrier apoptosis assay on cells
Key Factors in Experimental Design
-
Selection of the appropriate cell type. The toxic effects of nanoparticles depend to a large extent on the organ, and more specifically on the cell type encountered. Therefore, the selection of the appropriate cell type based on the targeted introduction method of the nanomaterial is an important factor in the cytotoxicity assay.
-
Select the suitable assay. The selection of an appropriate cytotoxicity assay is critical for the accurate assessment of nanoparticle toxicity. Various assays can be used to study the toxic effects of nanoparticles on cell cultures, including lactate dehydrogenase (LDH) leakage, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and identification of cytokine/chemokine production.
-
Select the correct dose for testing. Nanoparticle toxicity has been shown to act in a concentration-dependent manner, therefore, determining the appropriate nanoparticle dose for cytotoxicity assays is key to understanding the toxic effects of nanoparticles under real-world conditions.
Contact us
CD Bioparticles has developed a unique testing process based on many years of experience in aptamer and nanocarrier-coupled cytotoxicity assays, and we are confident that we can provide you with a one-stop shop for your research. If you are interested in our services, please do not hesitate to contact us for more detailed information.
Quotations and Ordering
Reference
-
Gutiérrez-Santana JC, Toscano-Garibay JD, López-López M, et al. Aptamers coupled to nanoparticles in the diagnosis and treatment of microbial infections. Enferm Infecc Microbiol Clin. 2020; 38 (7): 331-337.
